Under the agreement, Systagenix will co-market EpiFix, MiMedx’s proprietary biologic implant processed from amniotic tissue. Systagenix will conduct the first phase of the EpiFix global launch throughout the United States, followed by other countries.
MiMedx will continue selling EpiFix through existing distributor channels.
More Articles on Orthopedic Devices:
US Implantable Medical Devices Demand to Increase 7.7% Annually Through 2015
Exactech’s Deferred Prosecution Agreement Expires
BioMimetic Reports 2011 Revenue
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
